← back to search

Even H. Rustad

Oslo University Hospital · NO
Area of research
Hematology · Molecular Biology
Research interest
Research interests include Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, HIV/AIDS drug development and treatment, and Acute Myeloid Leukemia Research.
h-index
15
citations
903
works
296
NIH funding
primary concept
email

Recent publications

Non-viral vectors for chimeric antigen receptor immunotherapy
Nature Reviews Methods Primers 2024cited by 12position: middledoi
A T cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo
Nature Cancer 2023cited by 34position: middledoi
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma
Blood Advances 2023cited by 27position: middledoi
Extreme body mass index and survival in newly diagnosed multiple myeloma patients
Blood Cancer Journal 2023cited by 23position: middledoi
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
JAMA Oncology 2021cited by 117position: middledoi
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial
The Lancet Haematology 2021cited by 93position: middledoi
Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma
Nature Communications 2021cited by 51position: middledoi
mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies
Communications Biology 2021cited by 49position: firstdoi
Chromothripsis as a pathogenic driver of multiple myeloma
Seminars in Cell and Developmental Biology 2021cited by 39position: middledoi
Positive selection as the unifying force for clonal evolution in multiple myeloma
Leukemia 2021cited by 18position: middledoi
Timing the initiation of multiple myeloma
Nature Communications 2020cited by 162position: firstdoi
Accelerated single cell seeding in relapsed multiple myeloma
Nature Communications 2020cited by 80position: middledoi
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
JAMA Oncology 2019cited by 96position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ola Landgren · Miami University6 papers (2019–2023)Francesco Maura · Palmetto General Hospital5 papers (2021–2023)Gareth J. Morgan · Amyloidosis Foundation3 papers (2021–2021)Kylee Maclachlan · Memorial Sloan Kettering Cancer Center3 papers (2021–2021)Bachisio Ziccheddu · University of Miami Health System2 papers (2021–2021)Sean M. Devlin · Cornell University2 papers (2019–2023)Dickran Kazandjian · University of Miami2 papers (2019–2023)Niccolò Bolli · University of Milan2 papers (2021–2021)Patrick Blaney · University of Minnesota, Twin Cities2 papers (2021–2021)Sham Mailankody · Weill Cornell Medicine2 papers (2019–2023)Benjamin Diamond · University of Miami2 papers (2021–2021)Eileen M. Boyle · Curtin University2 papers (2021–2021)Malin Hultcrantz · Memorial Sloan Kettering Cancer Center2 papers (2019–2021)Ahmet Doǧan · Kettering Medical Center2 papers (2019–2021)Alexander M. Lesokhin · Weill Cornell Medicine2 papers (2021–2023)Magnus Björkholm · Svenska Örtmedicinska Institute1 papers (2019–2019)Nicole Gormley · United States Food and Drug Administration1 papers (2023–2023)Lakshmi V. Ramanathan · Vellore Institute of Technology University1 papers (2019–2019)Ferran Nadeu · Centro de Investigación Biomédica en Red1 papers (2021–2021)Daniel Auclair · Massachusetts Institute of Technology1 papers (2023–2023)